JP5687186B2 - 心臓及び発作（ｓｔｒｏｋｅ）のリスクのための予後診断及び診断マーカーとしてのリポカリン−２ - Google Patents

心臓及び発作（ｓｔｒｏｋｅ）のリスクのための予後診断及び診断マーカーとしてのリポカリン−２ Download PDF

Info

Publication number
JP5687186B2
JP5687186B2 JP2011506552A JP2011506552A JP5687186B2 JP 5687186 B2 JP5687186 B2 JP 5687186B2 JP 2011506552 A JP2011506552 A JP 2011506552A JP 2011506552 A JP2011506552 A JP 2011506552A JP 5687186 B2 JP5687186 B2 JP 5687186B2
Authority
JP
Japan
Prior art keywords
lipocalin
level
subject
risk
cardiovascular disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011506552A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011519037A5 (https=
JP2011519037A (ja
Inventor
アイミン・シュー
ユ・ワン
ラインハルト・レンネベルク
ジョージ・ウィリアム・ハンター・コーサーリー
プイイー・カンゲル・チャン
マティアス・レーマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Versitech Ltd
Original Assignee
Versitech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Versitech Ltd filed Critical Versitech Ltd
Publication of JP2011519037A publication Critical patent/JP2011519037A/ja
Publication of JP2011519037A5 publication Critical patent/JP2011519037A5/ja
Application granted granted Critical
Publication of JP5687186B2 publication Critical patent/JP5687186B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011506552A 2008-04-30 2009-04-16 心臓及び発作（ｓｔｒｏｋｅ）のリスクのための予後診断及び診断マーカーとしてのリポカリン−２ Expired - Fee Related JP5687186B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/113,056 US8030097B2 (en) 2008-04-30 2008-04-30 Lipocalin-2 as a prognostic and diagnostic marker for heart and stroke risks
US12/113.056 2008-04-30
PCT/CN2009/000405 WO2009132510A1 (en) 2008-04-30 2009-04-16 Lipocalin-2 as a prognostic and diagnostic marker for heart and stroke risks

Publications (3)

Publication Number Publication Date
JP2011519037A JP2011519037A (ja) 2011-06-30
JP2011519037A5 JP2011519037A5 (https=) 2013-06-13
JP5687186B2 true JP5687186B2 (ja) 2015-03-18

Family

ID=41254765

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011506552A Expired - Fee Related JP5687186B2 (ja) 2008-04-30 2009-04-16 心臓及び発作（ｓｔｒｏｋｅ）のリスクのための予後診断及び診断マーカーとしてのリポカリン−２

Country Status (5)

Country Link
US (1) US8030097B2 (https=)
EP (1) EP2300048A4 (https=)
JP (1) JP5687186B2 (https=)
CN (1) CN102026655A (https=)
WO (1) WO2009132510A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX340916B (es) 2008-01-18 2016-07-29 President And Fellows Of Harvard College * Metodos para detectar señales de identificacion de enfermedad o condiciones en fluidos corporales.
US20120219561A1 (en) * 2009-07-31 2012-08-30 Ingeneron, Inc. Prophylaxis Against Cancer Metastasis
CA2780301A1 (en) 2009-11-13 2011-05-19 Bg Medicine, Inc. Risk factors and prediction of myocardial infarction
US20110269150A1 (en) * 2010-02-10 2011-11-03 Cleveland Heart Lab Compositions and methods for predicting cardiovascular events
US8383580B2 (en) 2010-06-10 2013-02-26 The Regents Of The University Of Michigan Methods of administering lipocalins to treat metabolic disorders and cardiovascular diseases
AU2011280997A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
TW201209171A (en) 2010-07-23 2012-03-01 Harvard College Methods of detecting diseases or conditions using phagocytic cells
US20130203624A1 (en) 2010-07-23 2013-08-08 President And Fellows Of Harvard College Methods of Detecting Prenatal or Pregnancy-Related Diseases or Conditions
EP2596132A4 (en) 2010-07-23 2013-12-18 Harvard College METHOD FOR DETECTING SIGNS FOR ILLNESS OR SUFFERING IN BODY FLUIDS
AU2011281012A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting cardiovascular diseases or conditions
WO2012042061A1 (en) * 2010-10-01 2012-04-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the progression and treating a chronic kidney disease in a patient
US9533041B2 (en) * 2010-12-03 2017-01-03 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of heart failure
CA2827511A1 (en) * 2011-02-22 2012-08-30 Innavirvax A method for the prognosis of progression of the hiv disease
ES2777002T3 (es) * 2011-09-30 2020-08-03 Somalogic Inc Predicción de eventos de riesgo cardiovascular y usos de la misma
US9212361B2 (en) 2012-04-19 2015-12-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and pharmaceutical compositions for the treatment of hypertension
MX2014015434A (es) 2012-06-15 2015-07-14 Harry Stylli Metodos para detectar enfermedades o condiciones utilizando celulas enfermas en circulacion.
JP2015522260A (ja) 2012-06-15 2015-08-06 ハリー スティリ， 疾患または状態を検出する方法
US9594083B2 (en) * 2012-09-28 2017-03-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method for the treatment of cardiovascular fibrosis
NZ771629A (en) 2013-03-09 2022-12-23 Harry Stylli Methods of detecting cancer
WO2014164362A1 (en) 2013-03-09 2014-10-09 Harry Stylli Methods of detecting prostate cancer
US10626464B2 (en) 2014-09-11 2020-04-21 Cell Mdx, Llc Methods of detecting prostate cancer
US20200057075A1 (en) * 2017-02-20 2020-02-20 The Regents Of The University Of California Serologic assay for silent brain ischemia
KR102443523B1 (ko) * 2020-11-24 2022-09-15 경상국립대학교산학협력단 리포칼린-2 단백질을 이용한 발작에 의한 뇌신경세포 사멸 예측 또는 진단을 위한 정보제공방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2381551T3 (es) * 2003-12-05 2012-05-29 The Cleveland Clinic Foundation Marcadores de riesgo para enfermedad cardiovascular
US20050244892A1 (en) * 2004-02-27 2005-11-03 Lazar Mitchell A Resistin as a marker and therapeutic target for cardiovascular disease
CN101010001A (zh) * 2004-05-06 2007-08-01 哥伦比亚大学受托人 Ngal用于减少和改善局部缺血和肾中毒损伤
CA2565701A1 (en) * 2004-05-06 2005-11-17 Jonathan M. Barasch Ngal for reduction and amelioration of ischemic and nephrotoxic injuries
WO2006084142A2 (en) * 2005-02-04 2006-08-10 The Scripps Research Institute Dyslipoproteinemia associated with venous thrombosis
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
EP2062054A1 (en) * 2006-09-05 2009-05-27 Beth Israel Deaconess Medical Center, Inc. Use of lipocalin 2 in the regulation of insulin sensitivity
KR100819122B1 (ko) * 2006-09-30 2008-04-04 남명진 췌장암 진단용 키트
US7645616B2 (en) * 2006-10-20 2010-01-12 The University Of Hong Kong Use of lipocalin-2 as a diagnostic marker and therapeutic target
EP2095106B1 (en) * 2006-11-14 2013-03-20 Alere San Diego, Inc. Methods and compositions for diagnosis and prognosis of renal artery stenosis
WO2008060607A2 (en) * 2006-11-14 2008-05-22 Biosite Incorporated Methods and compositions for monitoring and risk prediction in cardiorenal syndrome

Also Published As

Publication number Publication date
US20090274709A1 (en) 2009-11-05
US8030097B2 (en) 2011-10-04
CN102026655A (zh) 2011-04-20
JP2011519037A (ja) 2011-06-30
WO2009132510A1 (en) 2009-11-05
EP2300048A1 (en) 2011-03-30
EP2300048A4 (en) 2011-08-24

Similar Documents

Publication Publication Date Title
JP5687186B2 (ja) 心臓及び発作（ｓｔｒｏｋｅ）のリスクのための予後診断及び診断マーカーとしてのリポカリン−２
JP2011519037A5 (https=)
KR101678703B1 (ko) 갈렉틴-３ 면역검정
CN102939541B (zh) 手术后急性肾损伤的预测和识别
US8361732B2 (en) Combination of sPLA2 activity and oxPL/apoB cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event
WO2008061149A2 (en) Methods and compositions for diagnosis and prognosis of renal artery stenosis
CN103370619A (zh) 诊断或风险预测心力衰竭的方法和试剂
JP4689651B2 (ja) 急性肺塞栓症用生化学マーカー
KR20170072215A (ko) 생물마커 및 예측 방법
US9347959B2 (en) Oxidative biomarkers in predicting risk of stroke, transient ischemic attack (TIA) and peripheral arterial disease (PAD)
JP4927093B2 (ja) 可溶性アジポネクチンレセプターペプチドの検出ならびに診断および治療における使用
JP2011521248A (ja) メタボリックシンドロームを有する患者及び有しない患者のリスク分析
JP7399431B2 (ja) 動脈硬化及び動脈硬化関連疾患マーカー
US20110082349A1 (en) Means and methods for determining the arteriosclerotic stenosis using inflammatory biomarkers
JP5369118B2 (ja) バイオマーカーｐｌｇｆを用いてアテローム性動脈硬化負荷を決定する手段及び方法
US8383355B2 (en) Combination of sPLA2 type IIA mass and OXPL/APOB cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event
WO2011038786A1 (en) COMBINATION OF sPLA2 TYPE IIA MASS AND OXPL/APOB CARDIOVASCULAR RISK FACTORS FOR THE DIAGNOSIS/PROGNOSIS OF A CARDIOVASCULAR DISEASE/EVENT
EP2385372A1 (en) Kidney disease in normal and abnormal pregnancy
HK1118902A (en) Biochemical markers for acute pulmonary embolism
HK1182443B (en) Prediction and recognition of acute kidney injury after surgery
WO2010018123A1 (en) Retinol binding protein 4 as a marker of peripheral insulin resistance in type 1 diabetes

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120217

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20121220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130321

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130328

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20130422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140731

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141222

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150121

R150 Certificate of patent or registration of utility model

Ref document number: 5687186

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees